Please login to the form below
systemic lupus erythematosus
This page shows the latest systemic lupus erythematosus news and features for those working in and with pharma, biotech and healthcare.
New data backs Merck’s segue into MS with BTK inhibitor
That mechanism also forms the basis of Merck’s testing of evobrutinib in rheumatoid arthritis and systemic lupus erythematosus (SLE), also at the phase 2 stage.
Latest news
-
BMS psoriasis drug hits the mark in phase II
BMS also has phase II studies of the drug ongoing in other indications including systemic lupus erythematosus and Crohn's disease.
-
AstraZeneca’s Lupus treatment misses mark in trial
lupus erythematosus (SLE). ... control. The result of this trial is disappointing for patients and the lupus community.”.
-
Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi
Ablynx also has vobarilizumab for systemic lupus erythematosus in phase II, with results due in the first half of the year that will trigger an option decision by AbbVie.
-
GSK closes in on EU approval for triple COPD therapy
Benlysta is used as an add-on treatment for adults with active, autoantibody-positive systemic lupus erythematosus (SLE).
-
Celgene pays $300m upfront for immunology start-up Delinia
The drug has potential in a variety of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, says Celgene, which also claims rights to related second-generation candidates.
More from news
Approximately 2 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
Pharma deals during September 2012
In a similar vein, Biogen Idec has sold its royalty rights to Benlysta (belimunab) for the treatment of systemic lupus erythematosus, to DRI Capital Managed Fund. ... Royalty monetisation. Benlysta (belimunab) for the treatment of systemic lupus
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Santhera CEO Klaus Schollmeier joins SuppreMol
This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
